OIFE advocates for patient involvement in all clinical trials and research for Osteogenesis Imperfecta (OI) and other rare diseases. Advanced Therapy Medicinal Products (ATMPs) are innovative medicines for human use based on genes, cells, or tissues. This includes stem cells, that are currently being researched for OI. EURORDIS hosted two webinars about the topic: Webinar…
OIFE was represented by Alessandra Tolaccia at the webinar about patient involvement in ATMP, which means Advanced Therapy Medicinal Products, which are innovative medicines for human use based on genes, cells, or tissues. This includes stem cells, that are currently being researched for OI. The first webinar in this series brought together patients, researchers and…
Heavy snowfall didn’t stop osteogenesis imperfecta from being well represented at an educational seminar on challenges and possibilities in advanced therapies. The event was hosted on 13 March 2023 by Oslo University Hospital in Norway. Rebecca Tvedt Skarberg was on the organizing committee, Inger-Margrethe Stavdal Paulsen from Norsk Forening for Osteogenesis Imperfecta (NFOI) gave a talk about…
